ERBB2 and breast neoplasm: In the present study, we showed for the first time that immunoconjugates expressing multimeric complement‐activating FHR4 and anti‐HER2 anchoring moieties were able to lyse targeted HER2‐expressing breast tumour cells in vitro through CDC using the activation of the AP.